GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (LSE:SNG) » Definitions » Net Income Including Noncontrolling Interests

Synairgen (LSE:SNG) Net Income Including Noncontrolling Interests : £-6.92 Mil (TTM As of Jun. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Synairgen Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Synairgen's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2024 was £-3.26 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 was £-6.92 Mil.

Synairgen Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Synairgen's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synairgen Net Income Including Noncontrolling Interests Chart

Synairgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.89 -13.92 -48.66 -17.65 -8.41

Synairgen Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.41 -5.24 -4.75 -3.66 -3.26

Synairgen Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-6.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synairgen Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Synairgen's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Synairgen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (LSE:SNG) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
LSE:FAB LSE:APTA LSE:CIZ LSE:GENF LSE:ROQ LSE:IMM AQSE:INC LSE:OBD LSE:IXI LSE:BSFA VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
SYGGF:USA OMY:Germany
Address
Southampton General Hospital, Tremona Road, Mailpoint 810, Level F, South Block, Southampton, GBR, SO16 6YD
Website
https://www.synairgen.com
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.

Synairgen Headlines

No Headlines